A Phase 3 interventional study of Dostarlimab and Carboplatin and paclitaxel in Endometrial Carcinoma and Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing dostarlimab in Endometrial Neoplasms — 12 open to participants now, 17 under way, 3 of them phase 3. dostarlimab · Endometrial Neoplasms.
Among the 18 studies testing dostarlimab in Endometrial Neoplasms, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 15 of the 16 other live ones, and was the 17th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →12 of the 18 studies testing dostarlimab in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in China
Ages 18+ · Women only
Queensland Centre for Gynaecological Cancer · Sites in Australia
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
dostarlimab: first FDA approval 2021 (JEMPERLI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dostarlimab is the treatment under test here. Read study by study →
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 3 · Phase 4 2
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 378 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 46 across the 18 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
13 studies in Endometrial Neoplasms by GlaxoSmithKline: 7 open now, 10 under way, 3 of them phase 3. Of 3 finished, 1 (33%) have results posted.
Among the 13 studies in Endometrial Neoplasms by GlaxoSmithKline, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 3 in phase 3, and was the 13th registered.
GlaxoSmithKline’s Endometrial Neoplasms studies by the year they started, since 2005.
7 of the studies testing dostarlimab in Endometrial Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04165772Memorial Sloan Kettering Cancer CenterStudy of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | 2026-11-30 |
| NCT06317311GlaxoSmithKlineA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | 2026-12-14 |
| NCT06897527GlaxoSmithKlineA Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC) | 2027-01-13 |
| NCT04774419Memorial Sloan Kettering Cancer CenterRadiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | 2027-02 |
| NCT05819892M.D. Anderson Cancer CenterPhase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 18 studies testing dostarlimab in Endometrial Neoplasms, from their registry updates:
Among GlaxoSmithKline’s 13 in Endometrial Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an open-label study, meaning both the researchers and participants will know which treatment is being given.
The study has two parts. In Part 1, researchers will identify the most suitable SC dose. In Part 2, participants will be randomly assigned by chance to receive dostarlimab as either an SC injection or an IV infusion. All participants will also receive carboplatin and paclitaxel. Treatment may continue for up to 3 years, with participants closely monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SC dostarlimab in Cohorts 1, 2, 4, 5 and 6, at different doses, to determine the doses of SC dostarlimab that will yield drug exposures comparable to approved IV dosing regimens. Participants in Cohort 3 will receive IV dostarlimab. Participants in all cohorts will receive carboplatin and paclitaxel. After 6 cycles, all participants will receive IV dostarlimab for up to 3 years until progression, death, or intolerable toxicities.
Biological: Dostarlimab · Drug: Carboplatin and paclitaxel
Eligible participants will be randomly assigned to receive either SC dostarlimab or IV dostarlimab (standard of care arm) in a 1:1 ratio. Participants randomized to the experimental arm will receive SC dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by SC dostarlimab monotherapy for up to 3 years of treatment in total. Participants randomized to the standard of care arm will receive IV dostarlimab in combination with carboplatin and paclitaxel for 6 cycles, followed by IV dostarlimab monotherapy for up to 3 years of treatment in total.
Biological: Dostarlimab · Drug: Carboplatin and paclitaxel
Dostarlimab will be administered as SC injection and IV infusion
Drug pages: Carboplatin · Paclitaxel
Carboplatin and paclitaxel will be administered as an IV infusion
Part 1: Serum Trough Concentration (Ctrough) After First Dose of Dostarlimab
Time frame: Up to 42 days
Part 1: Area Under the Concentration-time Curve (AUC) of Dostarlimab
Time frame: Up to 42 days
Part 2: Observed Ctrough of Dostarlimab
Time frame: Up to 168 days
Part 2: Model-predicted (MP) AUC of Dostarlimab
Time frame: Up to 21 days
Part 2: MP AUC of Dostarlimab
Time frame: Up to 168 days
Part 1: Ctrough of Dostarlimab
Time frame: Up to 42 days
Part 1: AUC of Dostarlimab
Time frame: Up to 42 days
Part 1: Maximum Observed Concentration (Cmax) of Dostarlimab
Time frame: Up to 42 days
Part 1: Time to Peak Drug Concentration (Tmax) of Dostarlimab
Time frame: Up to 42 days
Parts 1 and 2: Number of Participants Experiencing Adverse Events (AEs), Serious AEs (SAEs), Treatment-emergent AEs (TEAEs) and Immune-mediated AEs (imAEs)
Time frame: Up to 39 months
Parts 1 and 2: Number of Participants with TEAEs Leading to Infusion or Injection Interruption, Dose Modifications, Trial Intervention Discontinuation, or Death
Time frame: Up to 39 months
Parts 1 and 2: Confirmed Overall Response Rate (ORR)
Confirmed ORR is defined as the percentage of participants reaching confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1 by blinded independent central review (BICR) and investigator assessment
Time frame: Up to 3 years
Parts 1 and 2: Duration of Response (DoR)
DoR per RECIST 1.1 by BICR and investigator assessment is defined as the time from the date of first documented objective response of CR or PR that is subsequently confirmed until the date of first documented progressive disease (PD) or death due to any cause, whichever comes first
Time frame: Up to 3 years
Parts 1 and 2: Progression-free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per RECIST 1.1 by BICR and investigator assessment or death due to any cause, whichever comes first
Time frame: Up to 3 years
Parts 1 and 2: Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause
Time frame: Up to 3 years
Part 1: Number of Participants with Antidrug Antibody (ADAs) against Dostarlimab
Time frame: Up to 39 months
Part 2: Number of Participants with ADAs against Dostarlimab
Time frame: Up to 3 years
Part 2: MP Ctrough of Dostarlimab
Time frame: Up to 168 days
Part 2: MP Ctrough at Steady State of Dostarlimab
Time frame: Up to 168 days
Part 2: MP AUC at Steady State of Dostarlimab
Time frame: Up to 168 days
Part 2: MP Cmax of Dostarlimab
Time frame: Up to 168 days
No study locations are listed for this record.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2030, 47 months later.
Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 47 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dostarlimab · Carboplatin · Paclitaxel